Vivek Nanda
- Immunology top 5%
- Atherosclerosis and Cardiovascular Diseases 3
- Phagocytosis and Immune Regulation 2
- Cancer Research top 10%
-
- Coenzyme Q10 studies and effects 3
- RNA modifications and cancer 3
- Extracellular vesicles in disease 2
- Single-cell and spatial transcriptomics 2
- Genomics, phytochemicals, and oxidative stress 2
-
- Genetic Associations and Epidemiology 2
Vivek Nanda
20 papers receiving 1.2k citations
Hit Papers
Peers
Comparison fields: 5 of 102
- Immunology 576
- Cancer Research 301
- Molecular Biology 597
- Immunology and Allergy 41
- Cardiology and Cardiovascular Medicine 123
Countries citing papers authored by Vivek Nanda
This map shows the geographic impact of Vivek Nanda's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Vivek Nanda with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Vivek Nanda more than expected).
Fields of papers citing papers by Vivek Nanda
This network shows the impact of papers produced by Vivek Nanda. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Vivek Nanda. The network helps show where Vivek Nanda may publish in the future.
Co-authorship network
The 25 scholars most cited alongside Vivek Nanda, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
| # | Work | ||
|---|---|---|---|
| 1 | 2024 | 4 | |
| 2 | 2024 | 19 | |
| 3 | 2023 | 9 | |
| 4 | 2023 | 0 | |
| 5 | 2022 | 11 | |
| 6 | 2022 | 4 | |
| 7 | 2021 | 4 | |
| 8 | 2021 | 23 | |
| 9 | 2021 | 1 | |
| 10 | 2020 | 219 | |
| 11 | 2020 | 11 | |
| 12 | 2018 | 26 | |
| 13 | 2017 | 1 | |
| 14 | 2017 | 1 | |
| 15 | CD47-blocking antibodies restore phagocytosis and prevent atherosclerosisbreakdown → | 2016 | 500 |
| 16 | 2015 | 45 | |
| 17 | 2014 | 239 | |
| 18 | 2011 | 72 | |
| 19 | 2010 | 32 | |
| 20 | 1999 | 1 |
About Vivek Nanda
Vivek Nanda is a scholar working on Emergency Medicine, Immunology, Molecular Biology, Modeling and Simulation and Cardiology and Cardiovascular Medicine, having authored 21 papers that have together received 1.2k indexed citations. Recurring topics across this work include Coenzyme Q10 studies and effects (3 papers), Atherosclerosis and Cardiovascular Diseases (3 papers), RNA modifications and cancer (3 papers), Extracellular vesicles in disease (2 papers), Single-cell and spatial transcriptomics (2 papers), Genomics, phytochemicals, and oxidative stress (2 papers), Genetic Associations and Epidemiology (2 papers) and Phagocytosis and Immune Regulation (2 papers). The work is most often cited by research in Immunology (576 citations), Cancer Research (301 citations), Molecular Biology (597 citations), Immunology and Allergy (41 citations) and Cardiology and Cardiovascular Medicine (123 citations). Vivek Nanda has collaborated with scholars based in United States, Sweden and India. Frequent co-authors include Joseph M. Miano, Nicholas J. Leeper, Yoko Kojima, Jianqin Ye, Irving L. Weissman, Ulf Hedin, Lars Mäegdefessel, Ljubica Matic, Andrew J. Connolly and Daniel DiRenzo. Their work appears in journals such as Arteriosclerosis Thrombosis and Vascular Biology, Gene, PLoS Genetics, Circulation Research and International Journal of Infectious Diseases.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.